血液・血漿成分市場：製品、用途、エンドユーザー別-2025-2030年の世界予測

血液・血漿成分市場は、2023年に438億4,000万米ドルと評価され、2024年には458億6,000万米ドルに達すると予想され、CAGR 5.57％で成長し、2030年には641億1,000万米ドルになると予測されています。

血液・血漿成分市場には、医療・治療用途のための血液とその誘導体の分離、収集、使用が含まれます。この分野には、輸血、治療、診断に使用される全血、赤血球、血漿、血小板、その他の生物学的物質が含まれます。これらの成分の必要性は、医療緊急事態、手術、血友病のような慢性疾患、免疫不全への対応にあります。これらは病院、診断センター、研究機関などで集中的に使用されています。最終用途の範囲はヘルスケアプロバイダー、外来サービス、そして最近では新規治療法を分析するバイオテクノロジー企業にも広がっています。

主な成長要因としては、世界人口の高齢化による輸血・治療需要の増加、血漿誘導体の利用に関する研究の進展、慢性疾患の罹患率の増加などが挙げられます。血液検査や採取方法における技術的進歩も市場を強化しています。潜在的な治療機会は、血漿由来治療の拡大、ウイルス感染症に対する回復期血漿療法のような使用事例における技術革新の活用、血液成分サービスのインフラ整備が進む新興経済諸国への参入にあります。こうした機会を最大限に生かすには、業務の合理化のためにヘルスケアプロバイダーや規制機関との戦略的提携が有効であろう。

成長に影響を与えるトランスミッションには、成分生産の急速な拡大を妨げる可能性のある厳しい規制の枠組み、ドナーのサプライチェーン維持の課題、厳格なスクリーニングプロセスを必要とする疾病伝播のリスクなどがあります。市場の課題は、合成療法や代替療法との競争にも起因します。技術革新と研究開発の焦点は、採取方法の効率性と安全性の向上、携帯型採取装置の開発、AIを活用した在庫・需要予測の改善に向けられるべきです。ヘルスケアにおける重要な役割のため、市場は本質的に回復力があるが、成長を維持するためには技術や規制の変化への継続的な適応が必要です。こうした分野を理解し介入することで、サービス提供の改善と事業拡大を促進することができると思われます。

市場力学：急速に進化する血液・血漿成分市場の主要市場インサイトを公開

血液・血漿成分市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 外科手術の増加と安全性へのニーズ血液・血漿成分
  • 献血・血漿キャンペーンを奨励する政府の取り組み
  • 血液関連疾患および輸血医療の改善
• 市場抑制要因
  • 血液・血漿製剤の保管と保存期間に関する制約
• 市場機会
  • 採血、処理、保存技術の進歩
  • 免疫グロブリン補充療法と凝固因子濃縮製剤の新たな採用
• 市場の課題
  • 血液・血漿製品の安全性と品質を確保するための厳しい規制

ポーターのファイブフォース：血液・血漿成分市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血液・血漿成分市場における外部からの影響の把握

外部マクロ環境要因は、血液・血漿成分市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析血液・血漿成分市場における競合情勢の把握

血液・血漿成分市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス血液・血漿成分市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血液・血漿成分市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨血液・血漿成分市場における成功への道筋を描く

血液・血漿成分市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 外科手術の増加と安全の必要性血液・血漿成分
    • 政府の取り組みによる血液・血漿寄付キャンペーンの促進
    • 血液疾患と輸血医療の改善
  • 抑制要因
    • 血液および血漿製品の保管および保存期間に関する制限
  • 機会
    • 血液採取、処理、保管技術の進歩
    • 免疫グロブリン補充療法と凝固因子濃縮物の導入の台頭
  • 課題
    • 血液および血漿製品の安全性と品質を確保するための厳格な規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 血液・血漿成分市場：製品別

• 血漿由来
• 輸血

第7章 血液・血漿成分市場：用途別

• 血液学
• 固形腫瘍の管理

第8章 血液・血漿成分市場：エンドユーザー別

• 診断研究所
• 病院
• 調査機関
• 専門クリニック

第9章 南北アメリカの血液・血漿成分市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の血液・血漿成分市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの血液・血漿成分市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alfa Laval Corporate AB
• ANZCO Foods Limited
• Beckman Coulter, Inc.
• Becton, Dickinson & Co.
• Bio-Rad Laboratories, Inc.
• BioChemed Services
• bioMerieux SA
• Biowest Company
• CSL Behring LLC.
• Grifols, S.A.
• Immucor
• Lake Immunogenics, Inc.
• LAMPIRE Biological Laboratories, Inc.
• MacoPharma
• Meiji Holdings Co., Ltd.
• Moregate Biotech
• Octapharma AG
• Pel-Freez, LLC
• Rockland Immunochemicals, Inc. by BroadOak Capital Partners
• Sanquin
• TCS Biosciences Ltd.

LIST OF FIGURES

• FIGURE 1. BLOOD & PLASMA COMPONENTS MARKET RESEARCH PROCESS
• FIGURE 2. BLOOD & PLASMA COMPONENTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BLOOD & PLASMA COMPONENTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BLOOD & PLASMA COMPONENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BLOOD & PLASMA COMPONENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BLOOD & PLASMA COMPONENTS MARKET DYNAMICS
• TABLE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA-DERIVED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SOLID TUMOR MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. CANADA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. INDIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. ITALY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. POLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. QATAR BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. BLOOD & PLASMA COMPONENTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. BLOOD & PLASMA COMPONENTS MARKET, FPNV POSITIONING MATRIX, 2023

The Blood & Plasma Components Market was valued at USD 43.84 billion in 2023, expected to reach USD 45.86 billion in 2024, and is projected to grow at a CAGR of 5.57%, to USD 64.11 billion by 2030.

The blood and plasma components market involves the separation, collection, and use of blood and its derivatives for medical and therapeutic applications. This sector includes whole blood, red blood cells, plasma, platelets, and other biological materials used in transfusions, medical treatments, and diagnostics. The necessity of these components lies in addressing medical emergencies, surgeries, chronic conditions like hemophilia, and immune deficiencies. They are centrally applied in hospitals, diagnostic centers, and research institutions. End-use scope spans healthcare providers, ambulatory services, and increasingly biotech firms analyzing novel therapies.

Key growth factors include an aging global population increasing demand for transfusion and therapy, advancements in research into the use of plasma derivatives, and the growing incidence of chronic diseases. Technological advancements in blood testing and collection methods also enhance the market. Potential opportunities lie in expanding plasma-derived treatments, capitalizing on innovations in use-cases like convalescent plasma therapy for viral infections, and entering emerging economies where the infrastructure for blood component services is under development. To maximize these opportunities, strategic partnerships with healthcare providers and regulatory bodies for streamlined operations may be beneficial.

Limitations affecting growth include stringent regulatory frameworks that may impede rapid scaling of component production, the challenges in maintaining donor supply chains, and the risk of disease transmission which necessitates rigorous screening processes. Market challenges also stem from competition from synthetic and alternative therapies. Innovations and research focus should be directed towards improving the efficiency and safety of collection methods, developing portable collection devices, and leveraging AI for better inventory and demand forecasting. The market is inherently resilient, owing to its critical role in healthcare, but it requires ongoing adaptation to technological and regulatory changes to sustain growth. Understanding and intervening in these areas could facilitate improved service delivery and business expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood & Plasma Components Market

The Blood & Plasma Components Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing number of surgical procedures and need for safe blood & plasma components
  • Government initiatives encouraging blood & plasma donation campaigns
  • Improvements in blood-related disorders and transfusion medicine
• Market Restraints
  • Limitations associated with storage and shelf life of blood & plasma products
• Market Opportunities
  • Advancements in blood collection, processing, and storage technologies
  • Emerging adoption of immunoglobulin replacement therapy and clotting factor concentrates
• Market Challenges
  • Strict regulations to ensure the safety & quality of blood & plasma products

Porter's Five Forces: A Strategic Tool for Navigating the Blood & Plasma Components Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood & Plasma Components Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood & Plasma Components Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood & Plasma Components Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood & Plasma Components Market

A detailed market share analysis in the Blood & Plasma Components Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood & Plasma Components Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood & Plasma Components Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood & Plasma Components Market

A strategic analysis of the Blood & Plasma Components Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood & Plasma Components Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alfa Laval Corporate AB, ANZCO Foods Limited, Beckman Coulter, Inc., Becton, Dickinson & Co., Bio-Rad Laboratories, Inc., BioChemed Services, bioMerieux SA, Biowest Company, CSL Behring LLC., Grifols, S.A., Immucor, Lake Immunogenics, Inc., LAMPIRE Biological Laboratories, Inc., MacoPharma, Meiji Holdings Co., Ltd., Moregate Biotech, Octapharma AG, Pel-Freez, LLC, Rockland Immunochemicals, Inc. by BroadOak Capital Partners, Sanquin, and TCS Biosciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Blood & Plasma Components Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Plasma-Derived and Transfusion.
• Based on Application, market is studied across Hematology and Solid Tumor Management.
• Based on End User, market is studied across Diagnostics Laboratories, Hospitals, Research Institutions, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing number of surgical procedures and need for safe blood & plasma components
    • 5.1.1.2. Government initiatives encouraging blood & plasma donation campaigns
    • 5.1.1.3. Improvements in blood-related disorders and transfusion medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Limitations associated with storage and shelf life of blood & plasma products
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in blood collection, processing, and storage technologies
    • 5.1.3.2. Emerging adoption of immunoglobulin replacement therapy and clotting factor concentrates
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulations to ensure the safety & quality of blood & plasma products
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Blood & Plasma Components Market, by Product

• 6.1. Introduction
• 6.2. Plasma-Derived
• 6.3. Transfusion

7. Blood & Plasma Components Market, by Application

• 7.1. Introduction
• 7.2. Hematology
• 7.3. Solid Tumor Management

8. Blood & Plasma Components Market, by End User

• 8.1. Introduction
• 8.2. Diagnostics Laboratories
• 8.3. Hospitals
• 8.4. Research Institutions
• 8.5. Specialty Clinics

9. Americas Blood & Plasma Components Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Blood & Plasma Components Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Blood & Plasma Components Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alfa Laval Corporate AB
• 3. ANZCO Foods Limited
• 4. Beckman Coulter, Inc.
• 5. Becton, Dickinson & Co.
• 6. Bio-Rad Laboratories, Inc.
• 7. BioChemed Services
• 8. bioMerieux SA
• 9. Biowest Company
• 10. CSL Behring LLC.
• 11. Grifols, S.A.
• 12. Immucor
• 13. Lake Immunogenics, Inc.
• 14. LAMPIRE Biological Laboratories, Inc.
• 15. MacoPharma
• 16. Meiji Holdings Co., Ltd.
• 17. Moregate Biotech
• 18. Octapharma AG
• 19. Pel-Freez, LLC
• 20. Rockland Immunochemicals, Inc. by BroadOak Capital Partners
• 21. Sanquin
• 22. TCS Biosciences Ltd.